Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
10 juin 2024 14h30 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced new results from the INTEGUMENT-OLE long-term open-label study of investigational once-daily roflumilast cream 0.15%.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 juin 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
05 juin 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that five abstracts will be presented at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago June 8-10.
Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
03 juin 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that management will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, taking place June 10-13, 2024.
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter ended March 31, 2024, and provided a business update.
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
13 mai 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that the JCAD published an evaluation of formulation ingredients of ZORYVE (roflumilast) topical foam, 0.3%.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 mai 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
29 avr. 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024.
Arcutis Appoints David Topper as Chief Financial Officer
10 avr. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that David Topper has been appointed Chief Financial Officer effective April 10, 2024.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 avr. 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...